Skip to main content

Table 1 Patient Demographics and MDS Disease Characteristics

From: Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Age (years)
 Median (range) 75 (57−82)
Age (years) N (%)
 < 65 years 5 (26)
 ≥ 65 years 14 (74)
Gender
 Male 14 (74)
 Female 5 (26)
ECOG Performance Status
 0 13 (68)
 1 6 (32)
IPSS Classification
 Low Risk 5 (26)
 Intermediate-1 Risk 14 (74)
Baseline Cytogenetics
 Normal 14 (74)
 Abnormal 4 (21)
 Unknown 1 (5)
Transfusion Dependency
 RBC Transfusion Dependent 13 (68)
 Median (Range) 6 (4−10)
 Platelet Transfusion Dependent 2 (11)
WHO Classification
 RA 4 (21)
 RAEB-1 2 (11)
 RCMD 4 (21)
 RCMD-RS 5 (26)
 MDS-U 3 (16)
 MDS/MPD-U 1 (5)
Cell Lineage Cytopenia
 Unilineage Cytopenia 9 (47)
 Bilineage Cytopenia 6 (32)
 Trilineage Cytopenia 4 (21)
Baseline Cytopenia(s)
 Anemia only 9 (47)
 Anemia + Neutropenia 1 (5)
 Anemia + Thrombocytopenia 5 (26)
 Anemia + Neutropenia + Thrombocytopenia 4 (21)
Time from MDS Diagnosis (years)
 Median (range) .9 (.10 − 2.5)
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; IPSS International Prognostic Scoring System; RBC red blood cell; RA refractory anemia; RAEB-1 RA with excess blasts, type 1; RCMD refractory cytopenia with multilineage dysplasia; RCMD-RS RCMD with ringed sideroblasts; MDS-U myelodysplastic syndrome-unclassified; MDS/MPN-U MDS/myeloproliferative neoplasm-unclassified.